The Ministry of Public Health centre that coordinates clinical trials in Cuba and runs the Cuban Public Registry of Clinical Trials, set up in 2007 and listed by WHO as a primary registry.
The Cuban Public Registry of Clinical Trials (RPCEC) was established in 2007 under the leadership of the National Coordinating Centre of Clinical Trials (CENCEC) and has national coverage. Its home page states that a trial must obtain an RPCEC code before the first patient is recruited, as established by Resolution 435 of 2017 of the Ministry of Public Health, the clinical trials regulation, and that for trials authorised by CECMED the code must be sent to CECMED before it issues the authorisation certificate. Registered trials are not removed from public view, and sponsors submit their data in both Spanish and English. The registry shares a building with CECMED at Calle 5ta A, Miramar, Playa, Havana; the coordinates are approximate.
WHO lists the RPCEC among the primary registries of its International Clinical Trials Registry Platform. Earlier trials, such as the randomised trial of nimotuzumab with radiotherapy in high-grade glioma published in 2013, cite the Cuban National Register for clinical trials.
The main evidence for Cuba's lung cancer vaccine: well tolerated, with a survival gain that depends on how the analysis is done and that was clearest in patients who completed the induction doses.
A second Cuban therapeutic vaccine for lung cancer with randomised evidence of a modest survival gain, in a setting where few patients received further treatment at progression.
A small randomised trial of nimotuzumab with radiotherapy for high-grade glioma. Cuba's regulator CECMED lists adult high-grade glioma with radiotherapy among the indications of CIMAher (nimotuzumab), registered there since 19 February 2002.
Shares Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial, CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial, Ministry of Public Health, Cuba (MINSAP).
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial.
Shares Nimotuzumab or placebo with radiotherapy for high-grade glioma: a Cuban randomised double-blind trial, Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial, CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/